John M. Leonard - 20 Aug 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Reporting relationship: President and CEO, Director
Issuer ticker: NTLA
Reported as of: 20 Aug 2026
Net transaction value: -$286,819
SEC form: 4
Accepted by SEC: 24 Aug 2026, 16:05:04 UTC
Prior SEC filing: 27 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ James Basta, attorney-in-fact

Key filing fact

John M. Leonard filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 24 Aug 2026.

Key facts

This page summarizes John M. Leonard's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2026, 16:05.

Change

Previous filing in this sequence was filed on 27 Apr 2026.
Current net transaction value: -$286,819.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563584 Primary reporting owner

LEONARD JOHN M

Relationship: President and CEO, Director
Address: C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE
Signature: /s/ James Basta, attorney-in-fact
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Sale

Transaction value: $250,614
Shares: -19,890
Change %: -1.7%
Price: $12.60
Shares after: 1,149,849
Date: 20 Aug 2026
Ownership: Direct
Footnotes: F1, F2

NTLA transaction

Common Stock

Sale

Transaction value: $36,205
Shares: -2,785
Change %: -0.24%
Price: $13.00
Shares after: 1,147,064
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1

NTLA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 58,415
Date: 20 Aug 2026
Ownership: By Trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.

Footnote F3

Shares held by the John M. Leonard 2015 Irrevocable Trust.